drugset / Trial / NCT04609826
A Study of JNJ-74856665 in Participants With Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)
Non-randomizedSequentialOpen-labelTreatment
Summary
The purpose of this study is to determine the safety, tolerability, maximum tolerated doses (MTDs) and recommended Phase 2 doses (RP2Ds) of JNJ-74856665 as monotherapy and/or in combinations.
Timeline
- Start
- 2020-11-26
- Primary completion
- 2025-08-25
- Completion
- 2025-08-25
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Azacitidine | Other / unclassified | — | Intravenous |
| Subject | JNJ-74856665 | Unknown | — | Oral |
| Subject | Venetoclax | Small molecule | — | Oral |